Barclays raised the firm’s price target on TScan Therapeutics to $9 from $7 and keeps an Overweight rating on the shares following the Q4 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TCRX:
- TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Tscan Therapeutics, Inc. (TCRX) Q4 Earnings Cheat Sheet
- TScan Therapeutics presents Phase 1 clinical results on TSC-100, TSC-101
- TScan to host virtual KOL event to discuss Phase 1 heme malignancies study
- TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR
